Hunan Hansen Pharmaceutical Co (002412) Fair Value & Analysis
Healthcare · CN · Market cap 3.0B CNY
Fair value as of: Jul 22, 2026
From 26 valuation models · updated 20 days ago
Fair value updated Jul 22, 2026, revised from ¥8.26 to ¥7.95 (−3.8%) since Jun 25, 2026. Share price +21.2% over the past month.
A solid business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Our model range runs from ¥5.82 (bear) to ¥9.91 (bull), base ¥7.95. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 72/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range ¥4.08 – ¥8.34 · fair‑value band ¥5.82 – ¥9.91 · the ¥7.27 price screens below the ¥7.95 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.
Analysis
Hunan Hansen Pharmaceutical Co (002412) currently trades at ¥7.27, while our model-based Fair Value estimate is ¥7.95, implying the stock looks roughly 9.4% fairly valued today. The Quality Score stands at 72/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Hunan Hansen Pharmaceutical Co generated revenue of 1.0B CNY at a net margin of 21.8%. Revenue declined 2.3% year over year. It earns a return on equity of 9.8%. The balance sheet holds a net cash position of 43.5M CNY. Fundamentals as of Jul 22, 2026
Our scenario range runs from ¥5.82 (bear case) to ¥9.91 (bull case); at ¥7.27, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 11% below its 52-week high and 31% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 9%, 002412 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (¥7.87) versus Dividend Discount (¥0.0500). Highest evidence: Growth DCF (80).
Notify me when 002412 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 71 · Market factors (momentum, volatility) 58
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Hunan Hansen Pharmaceutical Co., Ltd. engages in the production and sale of traditional Chinese preparations in China and internationally. The company offers digestive system medicines; cardiovascular and cerebrovascular medicines; kidney-tonifying and urine-reducing medicines; trauma medicines; diagnostic medicines, etc.
Full company description
Hunan Hansen Pharmaceutical Co., Ltd. engages in the production and sale of traditional Chinese preparations in China and internationally. The company offers digestive system medicines; cardiovascular and cerebrovascular medicines; kidney-tonifying and urine-reducing medicines; trauma medicines; diagnostic medicines, etc. It provides medicines in injection, mixture, tablet, capsule, granule, syrup, decoction, tincture, and pill forms. Hunan Hansen Pharmaceutical Co., Ltd. is based in Yiyang, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Hunan Hansen Pharmaceutical Co reported revenue of ¥1.0B in FY2025 versus ¥892M in FY2021, a compound +3.9%/yr. Reported net income was ¥198M in FY2025, compounding +10.1%/yr from FY2021.
of which total revenue +3.5 pp · buybacks/dilution +0.0 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch 002412: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 623 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Hunan Hansen Pharmaceutical Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Hunan Hansen Pharmaceutical Co (002412) overvalued or undervalued?
What is the fair value of 002412?
What is the quality score of 002412?
What is the revenue of Hunan Hansen Pharmaceutical Co (002412)?
What is the net profit margin of 002412?
Does Hunan Hansen Pharmaceutical Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Hunan Hansen Pharmaceutical Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.